FAQ: Should Antibiotic Therapy be Continued in Patients Diagnosed with COVID-19?

  04 September 2020

The ability to streamline and de-escalate empiric antibiotic therapy remains a challenge for antimicrobial stewardship programs. This challenge is further complicated by the ongoing pandemic and increased concern for COVID-19 infection, especially in light of reported mortality rates associated with severe disease presentation. Providers may decide to continue antibiotic therapy in the setting of viral illness due to a concern for bacterial co-infection.

Viral and bacterial co-infections have been largely described in clinical literature for influenza although data can be found for other respiratory illnesses (i.e. RSV, rhinovirus, adenovirus).1 Prompt identification of bacterial infection in viral illness is critical as coinfection has been associated with increased rates of shock, required mechanical ventilation,
prolonged ICU stay, and increased mortality.

Author(s): Duke Antimicrobial Stewardship Outreach Network
Healthy Patients  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!